BrightPath Biotherapeutics Co., Ltd.
4594
Rank in Stocks
#24413
BrightPath Biotherapeutics Co., Ltd. specializes in the development of... BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
Share Price
$0.24052689
Last synced: 2026-11-10
Market Cap
$33.41M
Change (1 day)
2.70%
Change (1 year)
-37.19%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade BrightPath Biotherapeutics Co., Ltd. (4594)
Category
Healthcare
Operating Margin for BrightPath Biotherapeutics Co., Ltd. (4594)
Operating Margin as of November 2026 TTM: -2,575,346.77%
According to BrightPath Biotherapeutics Co., Ltd.'s latest financial reports, its current operating margin (TTM) is -2,575,346.77%. At the end of 2025 the company had an operating margin of -102,464.08%.
Operating Margin history for BrightPath Biotherapeutics Co., Ltd. from 2015 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -2,575,346.77% | 2,413.41% |
| 2025 | -102,464.08% | -93.61% |
| 2024 | -1,604,276.39% | 5,673.85% |
| 2023 | -27,785.21% | 190.04% |
| 2022 | -9,579.65% | -86.16% |
| 2021 | -69,201.36% | 327.93% |
| 2020 | -16,171.23% | 1,412.79% |
| 2019 | -1,068.97% | 142.58% |
| 2018 | -440.66% | 109.58% |
| 2017 | -210.26% | 74.93% |
| 2016 | -120.20% | 100.67% |
| 2015 | -59.90% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -100.00% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about BrightPath Biotherapeutics Co., Ltd.'s operating margin
What is BrightPath Biotherapeutics Co., Ltd.'s operating margin?
BrightPath Biotherapeutics Co., Ltd.'s operating margin is -2,575,346.77%, as of Nov 2026.
What was BrightPath Biotherapeutics Co., Ltd.'s operating margin in 2025?
In 2025, BrightPath Biotherapeutics Co., Ltd.'s operating margin was -102,464.08%, compared with -1,604,276.39% in 2024.
How has BrightPath Biotherapeutics Co., Ltd.'s operating margin changed since 2020?
From 2020 to 2025, BrightPath Biotherapeutics Co., Ltd.'s operating margin was highest in 2022 (-9,579.65%) and lowest in 2024 (-1,604,276.39%).
How does BrightPath Biotherapeutics Co., Ltd.'s operating margin compare with similar companies?
BrightPath Biotherapeutics Co., Ltd.'s operating margin (-2,575,346.77%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.